Ratings ImpediMed Limited

Equities

IPD

AU000000IPD8

Market Closed - Australian S.E. Other stock markets 11:40:57 27/06/2024 am IST			5-day change	1st Jan Change
0.071 ^AUD	+1.43%		-7.79%	-51.03%

07/06	ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director	CI
30/04	ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8%	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
IMPEDIMED LIMITED	-51.03%	94.15M	C
THERMO FISHER SCIENTIFIC	+5.16%	213B	B
DANAHER CORPORATION	+9.62%	188B	B-
INTUITIVE SURGICAL, INC.	+31.18%	157B	B-
BOSTON SCIENTIFIC CORPORATION	+33.37%	113B	A-
SIEMENS HEALTHINEERS AG	+4.83%	64.85B	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.51%	49.1B	B+
AGILENT TECHNOLOGIES, INC.	-4.27%	38.83B	A
GE HEALTHCARE TECHNOLOGIES INC.	+0.88%	35.6B	-
RESMED, INC.	+8.44%	27.4B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes